Stock LFMD LIFEMD, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings LifeMD, Inc.

Equities

LFMD

US53216B1044

Real-time Estimate Cboe BZX
Other stock markets
 20:50:40 06/05/2024 BST 		5-day change 1st Jan Change
12.33 USD -1.44% Intraday chart for LifeMD, Inc. +3.16% +47.71%
05-02 LifeMD, Inc. Announces A New Strategic Partnership Designed to Revolutionize Weight Management Patient Care CI
04-29 LifeMD, Inc. Appoints Calum Macrae to Its Board of Directors CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
LIFEMD, INC. Stock LifeMD, Inc.
+47.71% 512M -
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+5.33% 32.88B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+16.74% 7.84B
C-
SECTRA AB Stock Sectra AB
+23.16% 3.95B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-17.50% 3.11B
C-
OMNICELL, INC. Stock Omnicell, Inc.
-19.93% 1.38B
B
LUNIT INC. Stock Lunit Inc.
-30.65% 1.21B -
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
+7.55% 933M
C
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-33.44% 911M -
VERADIGM INC. Stock Veradigm Inc.
-26.12% 829M -
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LFMD Stock
  4. Ratings LifeMD, Inc.